Comparative Efficacy of Palonosetron–Dexamethasone Versus Granisetron–Dexamethasone for Prevention of Postoperative Nausea and Vomiting

Authors: Bairwa K et al.

Cureus 18(2): e104098, February 23, 2026

Summary

This narrative review compares the efficacy of palonosetron–dexamethasone versus granisetron–dexamethasone for prevention of postoperative nausea and vomiting (PONV), with specific emphasis on otologic surgeries such as tympanoplasty and mastoidectomy.

Otologic procedures carry particularly high PONV risk due to vestibular stimulation and frequent use of volatile agents and opioids. Even minor retching or vomiting can compromise graft integrity and surgical outcomes, making prolonged antiemetic protection clinically critical.

Pharmacologic Differences

Granisetron

• First-generation 5-HT3 receptor antagonist

• Competitive, reversible receptor blockade

• Plasma half-life ~9 hours

• Primarily effective for early PONV (0–6 hours)

Palonosetron

• Second-generation 5-HT3 receptor antagonist

• Allosteric binding with receptor internalization

• Plasma half-life ~40 hours

• Sustained receptor inhibition with superior delayed-phase protection (up to 48 hours)

Palonosetron’s longer receptor occupancy and higher binding affinity contribute to more consistent delayed PONV control.

Role of Dexamethasone

Dexamethasone enhances antiemetic efficacy via dual mechanisms:

Peripheral:

• Inhibits prostaglandin synthesis

• Reduces inflammatory mediator release

• Decreases serotonin release from enterochromaffin cells

Central:

• Acts on corticosteroid receptors

• Suppresses neuronal transmission in the nucleus tractus solitarius

A single 8 mg IV dose provides approximately 24–36 hours of protection and also improves postoperative recovery quality, appetite, and mild analgesia.

Combination Therapy

Because PONV is multifactorial, combining a 5-HT3 antagonist with dexamethasone offers synergistic suppression of serotonergic and inflammatory pathways.

Evidence synthesis from randomized trials and meta-analyses shows:

• Reduced early and delayed PONV

• Lower rescue antiemetic requirements

• Higher complete-response rates

In middle ear surgery specifically, cited trials showed:

• Palonosetron–dexamethasone: ~97% complete response at 24–48 hours

• Granisetron–dexamethasone: ~73% complete response

This difference is clinically meaningful in graft-sensitive otologic procedures.

Safety and Tolerability

Both regimens demonstrate excellent safety profiles.

Common mild adverse effects:

• Headache

• Dizziness

• Transient constipation

Palonosetron has lower association with QT prolongation compared to older 5-HT3 antagonists. Dexamethasone at prophylactic doses carries minimal risk, with rare transient hyperglycemia.

Cost-Effectiveness Considerations

Palonosetron has a higher acquisition cost. However, its prolonged duration:

• Reduces rescue antiemetics

• Shortens recovery burden

• Decreases complication-related risk (e.g., graft disruption)

Granisetron–dexamethasone remains appropriate and cost-effective for:

• Short-duration surgeries

• Lower-risk procedures

• Resource-limited settings

Risk-Stratified Clinical Application

The review supports individualized selection:

Granisetron–dexamethasone:

• Short or low-risk surgeries

• Early-phase PONV prevention

Palonosetron–dexamethasone:

• High-risk or prolonged procedures

• Otologic surgeries where delayed vomiting threatens graft stability

Evidence Gaps

The authors highlight:

• Predominance of small, single-center studies

• Need for multicenter randomized controlled trials

• Limited pediatric and geriatric data

• Sparse cost-utility analyses

• Need for studies on triple therapy (e.g., NK1 antagonists)

• Potential future role of personalized prophylaxis based on pharmacogenomics

Conclusions

Both regimens are effective and safe for PONV prevention. However, palonosetron–dexamethasone provides longer and more consistent protection, particularly valuable in otologic surgery where delayed vomiting may jeopardize surgical outcomes.

What You Should Know

• Combination therapy is superior to single agents for PONV.

• Palonosetron offers superior delayed-phase control.

• Particularly useful in middle ear surgery.

• Granisetron remains appropriate in lower-risk settings.

• Risk-stratified antiemetic selection optimizes clinical and economic outcomes.

Thank you to Cureus for publishing this focused review highlighting procedure-specific antiemetic strategy in otologic surgery.